Polymorphism in the β2-adrenergic receptor and lipoprotein lipase genes as risk determinants for idiopathic venous thromboembolism: A multilocus, population-based, prospective genetic analysis

Circulation

Volumn 113, Issue 18, 2006, Pages 2193-2200

  Zee, Robert Y L ^a   Cook, Nancy R ^a   Cheng, Suzanne ^b   Erlich, Henry A ^b   Lindpaintner, Klaus ^c   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Genetics; Multilocus; Polymorphisms; Risk factors; Venous thromboembolism

Indexed keywords

APOLIPOPROTEIN A4; BETA 2 ADRENERGIC RECEPTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; INTERLEUKIN 4 RECEPTOR; LIPOPROTEIN LIPASE; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; BLOOD CLOTTING FACTOR 5;

ADULT; ARTICLE; BLOOD CLOTTING; COHORT ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LUNG EMBOLISM; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL; STATISTICS; THROMBOEMBOLISM; THROMBOPHILIA; UNITED STATES; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR V; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; PHYSICIANS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, INTERLEUKIN-4; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; UNITED STATES; VENOUS THROMBOSIS;

EID: 33646799734     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.615401     Document Type: Article

References (28)

1. Final report on the aspirin component of the ongoing Physicians' Health Study: Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321:129-135.
2. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999;9:936-949.
3. Zee RY, Cook NR, Cheng S, Reynolds R, Erlich HA, Lindpaintner K, Ridker PM. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet. 2004;13:389-396.
4. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
5. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6: 461-464.
6. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
7. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
8. Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55:997-1004.
9. Devlin B, Bacanu SA, Roeder K. Genomic control to the extreme. Nat Genet. 2004;36:1129-1130; author reply 1131.
10. Liggett SB. β(2)-Adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med. 2000;161:S197-S201.
11. Liggett SB. Pharmacogenetics of β-1- and β-2-adrenergic receptors. Pharmacology. 2000;61:167-173.
12. Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A. The Gly16→Arg16 and Gln27→Glu27 polymorphisms of β2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab. 2003;88:4862-4866.
13. Zee RY, Cook NR, Reynolds R, Cheng S, Ridker PM. Haplotype analysis of the β-2 adrenergic receptor gene and risk of myocardial infarction. Genetics. 2005;169:1583-1587 .
14. Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC. β2 Adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost. 2005;3:405-407.
15. Talmud PJ, Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol. 2001;12:405-409.
16. Kastelein JJ, Ordovas JM, Wittekoek ME, Pimstone SN, Wilson WF, Gagne SE, Larson MG, Schaefer EJ, Boer JM, Gerdes C, Hayden MR. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet. 1999;56:297-305.
17. Brousseau ME, Goldkamp AL, Collins D, Demissie S, Connolly AC, Cupples LA, Ordovas JM, Bloomfield HE, Robins SJ, Schaefer EJ. Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial. J Lipid Res. 2004;45:1885-1891.
18. Souverein OW, Jukema JW, Boekholdt SM, Zwinderman AH, Tanck MW. Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. Eur J Hum Genet. 2005;13:445-451.
19. Ejchel TF, Araujo LM, Ramos LR, Cendoroglo MS, de Arruda Cardoso Smith M. Association of the apolipoprotein A-IV:360 Gln/His polymorphism with cerebrovascular disease, obesity, and depression in a Brazilian elderly population. Am J Med Genet B Neuropsychiatr Genet. 2005;135:65-68.
20. Cendoroglo MS, Lahoz C, Martinez TL, Ordovas JM, Lamon-Fava S, Cupples LA, Wilson PW, Schaefer EJ. Association of apo A-IV 360 (Gln→His) polymorphism with plasma lipids and lipoproteins: the Framingham Offspring Study. Atherosclerosis. 2005;179:169-175.
21. Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, Kalogeris TJ. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest. 2004;114: 260-269.
22. Recalde D, Ostos MA, Badell E, Garcia-Otin AL, Pidoux J, Castro G, Zakin MM, Scott-Algara D. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2004;24:756-761.
23. Tanaka K, Roberts MH, Yamamoto N, Sugiura H, Uehara M, Mao XQ, Shirakawa T, Hopkin JM. Genetic variants of the receptors for thromboxane A2 and IL-4 in atopic dermatitis. Biochem Biophys Res Commun. 2002;292:776-780.
24. Mirel DB, Valdes AM, Lazzeroni LC, Reynolds RL, Erlich HA, Noble JA. Association of IL4R haplotypes with type 1 diabetes. Diabetes. 2002;51:3336-3341.
25. Bugawan TL, Mirel DB, Valdes AM, Panelo A, Pozzilli P, Erlich HA. Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am J Hum Genet. 2003;72:1505-1514.
26. Liu X, Beaty TH, Deindl P, Huang SK, Lau S, Sommerfeld C, Fallin MD, Kao WH, Wahn LJ, Nickel R. Associations between total serum IgE levels and the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in German children: the German Multicenter Atopy Study. J Allergy Clin Immunol. 2003;112:382-388.
27. Liu X, Beaty TH, Deindl P, Huang SK, Lau S, Sommerfeld C, Fallin MD, Kao WH, Wahn U, Nickel R. Associations between specific serum IgE response and 6 variants within the genes IL4, IL13, and IL4RA in German children: the German Multicenter Atopy Study. J Allergy Clin Immunol. 2004;113:489-495.
28. Forster T, Chapman K, Loughlin J. Common variants within the interleukin 4 receptor alpha gene (IL4R) are associated with susceptibility to osteoarthritis. Hum Genet. 2004;114:391-395.